Browse studies

Find your next paid study

1 recruiting study matching your filters

Usefulness of Tumor Heterogeneity Assessment in Patients With MCRPC Undergoing Radioligand Therapy With 177LU-PSMA-617 Using Serial 18F-DCFPYL, 18F-FDG and 18F-Fluciclovine PET/CT Predicting Clinical Outcome

This a single-center, prospective, exploratory study. Patients with metastatic castration-resistant prostate cancer (mCRPC) scheduled to undergo Lutetium label…

Prostatic NeoplasmsProstatic Neoplasms, Castration-ResistantMetastatic Prostate Cancer+8 more

Estimated

~$10 – $7,500

VA Greater Los Angeles Healthcare SystemNCT06706921